Pilot Study of the Impact of Rosuvastatin Administration on Residual Chronic Immune Activation Under Antiretroviral Therapy: CESAR (Crestor En Sus Des AntiRetroviraux)

Next Previous
Trial Profile

Pilot Study of the Impact of Rosuvastatin Administration on Residual Chronic Immune Activation Under Antiretroviral Therapy: CESAR (Crestor En Sus Des AntiRetroviraux)

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications HIV-1 infections
  • Focus Biomarker; Pharmacodynamics
  • Acronyms CESAR

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 13 Nov 2015 Status changed from recruiting to completed based on the full analysis set results published in the JAIDS.
    • 02 Nov 2015 Primary endpoint [Receptor activation (Coexpress activation markers: proportion of peripheral CD8 T cells that co-express the activation markers CD38 and HLA-DR.)] has not been met as per the results published in the JAIDS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top